SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John H. Farro who wrote (1734)2/14/1997 8:07:00 PM
From: John H. Farro   of 4342
 
There is one other point I forgot to make. Agouron (AGPH) is estimated to lose $2.84/share for 1997, yet their shares are trading at $92 and they have a market cap of almost $1 billion. This is because FDA aproval of their protease inhibitor, Viracept, is expected soon and because they have other drugs in the pipeline. I don't mean to compare PRLN with AGPH because PRLN will be marketing a health care supplement and not a drug. Comparing the two companies is like comparing apples and oranges. PRLN has a long way to go before before it is in the position AGPH is in. I am only pointing out that one does not need a positive P/E ratio to justify a higher share price if there is likely to be a large profit in the future.

Robin
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News